Chronic Myeloid Leukemia Committee (CML)


Frédéric Millot
since 2012, 2nd term

Clinical trials




Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, Plantaz D, Bertrand Y, Bordigoni P, Guilhot F. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 116:140-143 (2005)

Perseghin P, Gambacorti-Passerini C, Tornaghi L, Dassi M, Pioltelli P, Parma M, Colnaghi F, Giudici G, Elli E, Fumagalli M, Ponchio L, Biondi A, Pogliani EM. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Transfusion 45:1214-20 (2005)s

Millot, F., Guilhot, J., Nelken, B., Leblanc, T., De Bont, E.S., Békassy, A.N., Gadner, H., Sufliarska, S., Stary, J., Gschaidmeier, H., Guilhot, F., Suttorp, M. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase, and in relapse after stem cell transplantation. Leukemia 20: 187 – 192 (2006)

Millot F, Guilhot J, Nelken B, Leblanc T, Leverger G, Bernard F, Gandemer V, Béhard C, Berger C, Cornu G, Duchčne S, Guilhot F. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia. Pediatr Blood Cancer 47:555-559 (2006)

Suttorp M, Boehme J, Vaitl J, Mosch B, Pursche S, Jung R, Bergmann R, Fischer R, Pietzsch J, Bornhäuser M, Gasser JA. Side effects on the heart and skeleton of growing mice attributed to chronic imatinib exposure (Abstract). Blood 112:402 (2008)

Adler R, Viehmann S, Kuhlisch E, Martiniak Y,Röttgers S, Harbott J, Suttorp M. Correlation of BCR/ABL Transcript Variants with Patients’ Characteristics in Childhood Chronic Myeloid Leukaemia. Eur J Haematol 82:112-118 (2008)

Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen DW, Schrezenmeier H, Ehninger G, Müller C, Berger J, Suttorp M, Kolb HJ, Kröger N, Zander AR. The Changing Scene of Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia - a Report from the German Registry Covering the Period from 1998 to 2004. Ann Hematol 88:1237-1247(2009)

Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, Mazingue F, Lutz P, Vérité C, Berthoux C, Galambrun C, Bernard F, Yacouben K, Bordigoni P, Edan C, Reguerre Y, Couillaud G, Cayuela JM, Guilhot F. Imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in early chronic phase (CP): results of the French national phase IV trial (Abstract). Blood 114:863 (2009)

Suttorp M, Thiede C, Tauer JT, Roettgers S, Sedlacek P, Harbott J. Chronic Myeloid Leukemia in Pediatrics – First Results From Study CML-PAED II (Abstract). Blood 114:145 (2009)

Schmid H, Jaeger BA, Lohse J, Suttorp M. Longitudinal growth retardation in a prepupertal girl with chronic myeloid leukemia on long-term imatinib treatment. (Letter to the editor). Haematologica; 94: 1177-1179 (2009)

Jaeger B, Lohse J, Navratil K, Roesen-Wolff A, Suttorp M. Impact of imatinib on the in vitro osteoclastogenic differentiation of monocytes in children and adolescents with chronic myeloid leukemia (Abstract). Klin Padiatr 221:199 (2009)

Suttorp M, Claviez A, Bader P, Peters C, Gadner H, Ebell W, Dilloo D, Kremens B, Kabisch H, Führer M, Zintl F, Göbel U, Klingebiel T. Allogeneic stem cell transplantation for treatment of chronic myeloid leukemia in pediatric and adolescent patients: results of the prospective trial CML-paed I. Klin Padiatr 221:351-357 (2009)